Biosite pushes on with sepsis test:
This article was originally published in Clinica
Biosite is developing a three-biomarker point-of-care test that could help assess sepsis progression. Following the release of preliminary study data for the test, the firm claimed that it is "on track to launch a prospective multicentre clinical study in the second quarter of 2007." The study will form the basis of an US FDA submission, said the San Diego, California company. The test, called the Triage sepsis panel, consists of biomarkers neutrophil gelatinase-associated lipocalcin (NGAL), c-reactive protein (CRP) and macrophage inflammatory protein-3 (MIP-3).
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.